The abstract is read at the publisher; the summary is JClub's.
Extracellular vesicles from alternatively activated macrophages (AAM-EVs) are essential mediators of AAM therapy in established APAP liver injury, reducing necrosis and neutrophilic inflammation while promoting hepatocellular regeneration.
- Why it matters: AAMs are in clinical development for acute liver injury, but how they remodel the injured hepatic niche to drive repair is not fully understood.
- What they did: The study identified AAM-EVs as key effectors, showing they enhance macrophage phagocytosis and induce reparative transcriptional and proteomic programs, including increased TREM2 abundance; EV release inhibition and Dicer-deficient AAM EVs reduced activity.
- The result: After AAM-EV administration in established APAP injury, EVs rapidly associate with hepatic macrophages, shift them toward reparative phenotypes, and improve regeneration, supporting EV-mediated communication as a cell-free therapeutic strategy.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.